State Board of Administration of Florida Retirement System acquired a new position in shares of Relmada Therapeutics, Inc. (NASDAQ:RLMD – Get Rating) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 25,610 shares of the company’s stock, valued at approximately $486,000.
Several other large investors also recently modified their holdings of the company. RTW Investments LP increased its position in shares of Relmada Therapeutics by 16.2% during the first quarter. RTW Investments LP now owns 2,540,074 shares of the company’s stock worth $68,557,000 after buying an additional 353,750 shares during the period. BlackRock Inc. grew its holdings in Relmada Therapeutics by 41.0% in the first quarter. BlackRock Inc. now owns 1,952,808 shares of the company’s stock worth $52,707,000 after purchasing an additional 567,573 shares during the period. Vanguard Group Inc. grew its holdings in Relmada Therapeutics by 8.1% in the first quarter. Vanguard Group Inc. now owns 1,324,014 shares of the company’s stock worth $35,736,000 after purchasing an additional 99,113 shares during the period. Great Point Partners LLC grew its holdings in Relmada Therapeutics by 10.1% in the first quarter. Great Point Partners LLC now owns 790,000 shares of the company’s stock worth $21,322,000 after purchasing an additional 72,680 shares during the period. Finally, State Street Corp grew its holdings in Relmada Therapeutics by 37.8% in the first quarter. State Street Corp now owns 445,564 shares of the company’s stock worth $12,026,000 after purchasing an additional 122,163 shares during the period. 82.03% of the stock is currently owned by institutional investors and hedge funds.
Relmada Therapeutics Price Performance
Shares of NASDAQ RLMD opened at $5.94 on Friday. The stock has a market capitalization of $178.79 million, a P/E ratio of -1.02 and a beta of 0.06. The company has a 50-day moving average price of $18.83 and a 200-day moving average price of $21.52. Relmada Therapeutics, Inc. has a 1 year low of $5.62 and a 1 year high of $38.68.
Analysts Set New Price Targets
About Relmada Therapeutics
Relmada Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults.
- Get a free copy of the StockNews.com research report on Relmada Therapeutics (RLMD)
- MarketBeat: Week in Review 11/14 – 11/18
- Target’s Double Bottom Might Have Just Been Confirmed
- How High Can the Fed Go? How to Trade it
- Does ASML’s November Rally Have Staying Power?
- Verra Mobility Stock Has Returned Back to the Station
Receive News & Ratings for Relmada Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Relmada Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.